Literature DB >> 21327698

Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency.

Przemysław Miarka1, Barbara Idzior-Waluś2, Marek Kuźniewski1, Małgorzata Waluś-Miarka3, Tomasz Klupa3, Władysław Sułowicz1.   

Abstract

Familial lecithin-cholesterol acyltransferase (LCAT) deficiency (FLD) is a rare genetic disorder of lipid metabolism, characterised by low plasma HDL cholesterol, proteinuria, haemolytic anaemia and corneal opacities. Usually renal disease progresses during the third decade of life to renal failure; however the pathogenesis of renal disease is not well understood. In this study we describe treatment of renal disease in two siblings with FLD. The proband WX at the age of 31 years presented proteinuria and ankle oedema during her third pregnancy. Diagnosis of FLD was based on a renal biopsy with characteristic serpiginous fibrillar deposits under electron microscopy, markedly decreased HDL cholesterol, esterified cholesterol levels and LCAT activity, confirmed by molecular analysis. After 3 years her proteinuria increased and she received an ACE inhibitor to which she responded well. During further increases of proteinuria she additionally received methylprednisolone and her proteinuria decreased. This long-term observation indicates the efficacy of corticosteroids and renin-angiotensin-aldosterone system blockers in the treatment of proteinuria in patients with FLD. The results suggest the role of inflammatory processes as well as dyslipidemia in the pathogenesis of glomerular disorders in LCAT-deficient patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327698     DOI: 10.1007/s10157-011-0409-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  22 in total

Review 1.  Antiinflammatory properties of HDL.

Authors:  Philip J Barter; Stephen Nicholls; Kerry-Anne Rye; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman
Journal:  Circ Res       Date:  2004-10-15       Impact factor: 17.367

2.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

3.  Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B.

Authors:  E G Lynn; Y L Siow; J Frohlich; G T Cheung; K O
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

Review 4.  The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.

Authors:  J A Kuivenhoven; H Pritchard; J Hill; J Frohlich; G Assmann; J Kastelein
Journal:  J Lipid Res       Date:  1997-02       Impact factor: 5.922

Review 5.  Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics?

Authors:  Basit Javaid; Richard J Quigg
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

6.  Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency.

Authors:  T A Christiansen-Weber; J R Voland; Y Wu; K Ngo; B L Roland; S Nguyen; P A Peterson; W P Fung-Leung
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

Review 7.  Mechanisms of disease: proatherogenic HDL--an evolving field.

Authors:  Mohamad Navab; Gattadahalli M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Benjamin J Ansell; Alan M Fogelman
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-09

8.  Possible induction of renal dysfunction in patients with lecithin:cholesterol acyltransferase deficiency by oxidized phosphatidylcholine in glomeruli.

Authors:  S Jimi; N Uesugi; K Saku; H Itabe; B Zhang; K Arakawa; S Takebayashi
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

9.  Renal failure in familial lecithin: cholesterol acyltransferase deficiency.

Authors:  L K Borysiewicz; A K Soutar; D J Evans; G R Thompson; A J Rees
Journal:  Q J Med       Date:  1982

10.  Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs).

Authors:  P Aranda; P Valdivielso; L Pisciotta; I Garcia; C Garcã A-Arias; S Bertolini; G Martã N-Reyes; S Calandra
Journal:  Clin Nephrol       Date:  2008-03       Impact factor: 0.975

View more
  7 in total

1.  LCAT deficiency and pregnancy: Case report.

Authors:  Raul Leal-Gonzalez; Álvaro Ramos-Reyes; Mariana Moncada-Madrazo; Irasema Apodaca-Ramos; Kimberly L Morales-Palomino; Alejandro Valdés-Cepeda; César A Marrufo-García; Hugo A Rangel-Nava
Journal:  Obstet Med       Date:  2020-09-09

Review 2.  Approach to the patient with extremely low HDL-cholesterol.

Authors:  Daniel J Rader; Emil M deGoma
Journal:  J Clin Endocrinol Metab       Date:  2012-10       Impact factor: 5.958

3.  Novel Missense LCAT Gene Mutation Associated with an Atypical Phenotype of Familial LCAT Deficiency in Two Portuguese Brothers.

Authors:  I Castro-Ferreira; Rute Carmo; Sérgio Estrela Silva; Otília Corrêa; Susana Fernandes; Susana Sampaio; Rodrigues-Pereira Pedro; Augusta Praça; João Paulo Oliveira
Journal:  JIMD Rep       Date:  2017-10-06

Review 4.  Current Status of Familial LCAT Deficiency in Japan.

Authors:  Masayuki Kuroda; Hideaki Bujo; Koutaro Yokote; Takeyoshi Murano; Takashi Yamaguchi; Masatsune Ogura; Katsunori Ikewaki; Masahiro Koseki; Yasuo Takeuchi; Atsuko Nakatsuka; Mika Hori; Kota Matsuki; Takashi Miida; Shinji Yokoyama; Jun Wada; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-04-18       Impact factor: 4.928

5.  Familial lecithin-cholesterol acyltransferase (LCAT) deficiency; a differential of proteinuria.

Authors:  Mohammed Mahdi Althaf; Hadeel Almana; Ahmed Abdelfadiel; Sadiq Mohammed Amer; Turki Omar Al-Hussain
Journal:  J Nephropathol       Date:  2015-01-01

6.  Lipoprotein X Causes Renal Disease in LCAT Deficiency.

Authors:  Alice Ossoli; Edward B Neufeld; Seth G Thacker; Boris Vaisman; Milton Pryor; Lita A Freeman; Christine A Brantner; Irina Baranova; Nicolás O Francone; Stephen J Demosky; Cecilia Vitali; Monica Locatelli; Mauro Abbate; Carlamaria Zoja; Guido Franceschini; Laura Calabresi; Alan T Remaley
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

Review 7.  A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency.

Authors:  Cecilia Vitali; Archna Bajaj; Christina Nguyen; Jill Schnall; Jinbo Chen; Kostas Stylianou; Daniel J Rader; Marina Cuchel
Journal:  J Lipid Res       Date:  2022-01-20       Impact factor: 5.922

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.